Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Lantibio River Plate Biotechnology, Inc. Rx Development Resources, LLC |
---|---|
Information provided by: | Lantibio |
ClinicalTrials.gov Identifier: | NCT00599716 |
The study is designed to assess the safety and efficacy of Vismed®, a special eye drop containing sodium hyaluronate, in the treatment of dry eye syndrome. Vismed® is being compared to another eye drop, identical in composition except that it does not contain the active ingredient, sodium hyaluronate. This eye drop is designed as the "vehicle." Some subjects are to receive Vismed® treatment, while others are to receive the vehicle; the assignment of subjects to receive either Vismed or vehicle is to be random. The two-week treatment phase is followed by a one week follow-up period to evaluate safety of Vismed®.
Condition | Intervention | Phase |
---|---|---|
Dry Eye Disease |
Drug: sodium hyaluronate Drug: vehicle |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Multicenter, Randomized, Double-Masked Study of Safety and Efficacy of Vismed® in Dry Eye Syndrome |
Estimated Enrollment: | 300 |
Study Start Date: | December 2006 |
Study Completion Date: | May 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
study drug
|
Drug: sodium hyaluronate
a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
|
2: Placebo Comparator
vehicle control
|
Drug: vehicle
identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
|
VISMED® is currently marketed in Europe under the CE mark as a viscoelastic lubricant eye drop. The proprietary formulation contains a highly purified specific fraction of sodium hyaluronate. Sodium hyaluronate is a natural polymer which is also present in the structures of the human eye. Its main physical characteristic is viscoelasticity. This means that VISMED® has a high viscosity between blinks and a low viscosity during blinking ensuring efficient coating of the surface of the eye. It is believed that this protective coating of the surface of the eye helps prevent dryness and irritation. Sodium hyaluronate also possesses mucoadhesive properties and the ability to entrap water, thus resembling tear mucus glycoprotein. This, together with the coating properties of sodium hyaluronate, results in an increased pre-corneal residence time and tear film break-up time (BUT) and therefore longer lubrication of the eye surface. VISMED® is completely free of preservatives. As a result, it is non-irritating to ocular tissues and can be used frequently and for extended periods without harming the surface of the eye (e.g. without causing superficial punctate keratitis). Some preservatives are known to cause toxic or allergic reactions, the symptoms of which include stinging, burning and redness of the eyes. To further maximize patient comfort, the pH of VISMED® is adjusted to 7.3, similar to that of the natural tear film.
Hydrogels of sodium hyaluronate have been used for many years in ophthalmic surgery in Europe and the U.S. to maintain the shape of the eye, to cover surgical instruments and to protect the corneal endothelium from damage. They have unique physical properties that make them ideal for use in the treatment of Dry Eye Syndrome. Therefore, VISMED® represents a new class of compound in development for the treatment of dry eye in the US, offering lubricant properties which can alleviate the discomfort and reverse ocular damage caused by dry eye syndrome.
This study is being conducted to supplement the body of knowledge gained from studies conducted in Europe and regulatory approvals granted there to formalize the safety and efficacy of Vismed® to meet FDA requirements for a New Drug Application to market the product in the US.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Abrams Eye Center | |
Stuart, Florida, United States, 44115 | |
Center for Excellence in Eye Care | |
Miami, Florida, United States, 33176 | |
International Eye Center | |
Tampa, Florida, United States, 33603 | |
Florida Eye Microsurgical Institute | |
Boynton Beach, Florida, United States, 33426 | |
East Florida Eye Institutue | |
Stuart, Florida, United States, 34994 | |
United States, Indiana | |
American Eye Institute | |
New Albany, Indiana, United States, 47150 | |
United States, Missouri | |
Comprehensive Eye Care | |
Washington, Missouri, United States, 63090 | |
United States, North Carolina | |
Charlotte Eye, Ear, Nose and Throat | |
Charlotte, North Carolina, United States, 28210 | |
United States, Pennsylvania | |
Ophthalmic Research & Clinical Studies | |
Moon Twp, Pennsylvania, United States, 15108 | |
United States, Tennessee | |
Chattanooga Eye Institute | |
Chattanooga, Tennessee, United States, 37411 |
Study Chair: | Roger Vogel, MD | Rx Development Resources, LLC |
Study Director: | Terry Laliberte, BS | River Plate Biotechnology, Inc. |
Principal Investigator: | Charles (Andy) Kirby, MD | Chattanooga Eye Institute, Chattanooga, TN |
Principal Investigator: | Mark Abrams, MD | Abrams Eye Center, Cleveland, OH |
Responsible Party: | River Plate Biotechnology, Inc./Lantibio, Inc. ( Terry W. Laliberte/Director of Development ) |
Study ID Numbers: | RP-001 |
Study First Received: | January 11, 2008 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00599716 |
Health Authority: | United States: Food and Drug Administration |
dry eye syndrome dry eye disease Vismed |
dry eye sodium hyaluronate hyaluronic acid |
Hyaluronic Acid Eye Diseases Lacrimal Apparatus Diseases Dry Eye Syndromes Tetrahydrozoline |
Pathologic Processes Disease Immunologic Factors Syndrome |
Physiological Effects of Drugs Adjuvants, Immunologic Pharmacologic Actions |